Prevention and Intervention Approaches for Fetal Alcohol Spectrum Disorders (R61/R33 Clinical Trial Optional)
This grant supports research on preventing and treating fetal alcohol spectrum disorders (FASD) through a phased approach, with a focus on clinical trials.
Funder: National Institutes of Health
Due Dates: June 17, 2025 (New) | July 17, 2025 (Renewal/Resubmission/Revision) | October 17, 2025 (New) | November 18, 2025 (Renewal/Resubmission/Revision) | February 18, 2026 (New) | March 17, 2026 (Renewal/Resubmission/Revision) | June 17, 2026 (New) | July 17, 2026 (Renewal/Resubmission/Revision) | October 19, 2026 (New) | November 17, 2026 (Renewal/Resubmission/Revision) | May 18, 2025 (Letter of Intent)
Funding Amounts: R61 phase: up to $350,000 direct costs over 2 years (max $225,000/year); R33 phase: up to $500,000 direct costs/year for up to 3 years; total project period up to 5 years.
Summary: Supports phased research (R61/R33) on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD), with a strong emphasis on clinical trials.
Key Information: Highest priority is given to applications proposing clinical trials; transition from R61 to R33 is milestone-dependent and not guaranteed.
Description
This opportunity from the National Institute on Alcohol Abuse and Alcoholism (NIAAA) at NIH supports research on prevention and intervention strategies for fetal alcohol spectrum disorders (FASD) across the lifespan. The program uses the R61/R33 Exploratory/Developmental Phased Award mechanism, allowing for clinical trial or non-clinical trial applications.
The R61 phase (up to 2 years) is intended for pilot studies, secondary data analysis, or feasibility work to develop and test hypotheses. Successful completion of R61 milestones, as determined by NIAAA program staff, is required to transition to the R33 phase (up to 3 years), which supports further development, application, and evaluation of interventions or prevention strategies. The overall goal is to advance evidence-based approaches to reduce prenatal alcohol exposure and the incidence and impact of FASD.
Highest priority is given to applications that include clinical trials. Applicants interested in planning clinical trials or adding to current projects may also consider the companion R34 planning grant (PAR-25-159).
